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BACKGROUND: Several studies suggest links between cancer and tricyclic antidepressant use.
METHODS: A case–control study using the General Practice Research Database examined whether previous tricyclic usage was
associated with reduced incidence of brain (with glioma as a sub-category), breast, colorectal, lung and prostate cancers. Conditional
logistic regression adjusted for age, gender, general practice, depression, smoking, body mass index, alcohol use and non-steroidal
anti-inflammatory drug use.
RESULTS: A total of 31953 cancers were identified, each matched with up to two controls. We found a statistically significant reduction
in tricyclic prescriptions compared with controls in glioma (odds ratio (OR) ¼0.59, 95% confidence interval (CI)¼0.42–0.81) and
colorectal cancer patients (OR¼0.84, CI¼0.75–0.94). These effects were dose-dependent (P-values for trend, glioma¼0.0005,
colorectal¼0.001) and time-dependant (P-values for trend glioma¼0.0005, colorectal¼0.0086). The effects were cancer-type
specific, with lung, breast and prostate cancers largely unaffected by antidepressant use.
CONCLUSION: The biologically plausible, specific and dose- and time-dependant inverse association that we have found suggests that
tricyclics may have potential for prevention of both colorectal cancer and glioma.
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Prevention of disease is better than its cure. In the case of cancer,
where complete cure is often not possible, the strategies available
for cancer prevention are still limited. However, the vast numbers
of existing drugs used daily by millions of people are a potential
source of agents that may help to prevent or even treat cancer.
Despite notable examples of success such as the non-steroidal
anti-inflammatory drugs (NSAIDs) (Cuzick et al, 2009) and statins
(Kaye and Jick, 2004), few such agents have however yet been
discovered.
Tricyclic antidepressants (TCAs) are widely prescribed for a
variety of conditions, including depression, anxiety and insomnia.
Although tricyclics have received some attention in epidemiolo-
gical studies as possible carcinogens owing to their putative
genotoxic activity (van Schaik and Graf, 1991), these have been
inconclusive (Fulton-Kehoe et al, 2006; Xu et al, 2006; Tamim et al,
2007; Toh et al, 2007). There is substantial evidence that conflicts
with this carcinogenic view of tricyclics, as particularly chlorimipra-
mine (clomipramine), although also imipramine, citalopram,
amitriptyline and desipramine, have shown anticancer effects
(Xia et al, 1999; Arimochi and Morita, 2006). Tricyclics have
shown cytotoxic actions in various cancer cell lines including
glioma cells (Xia et al, 1999; Daley et al, 2005; Levkovitz et al, 2005)
and colorectal cancer cells (Arimochi and Morita, 2006), perhaps
attributable to inhibition of mitochondrial complex III activity,
leading to a decrease in mitochondrial membrane potential, and
apoptosis (Weinbach et al, 1986; Daley et al, 2005). Animal studies
substantiate an anticancer action in overcoming drug resistance in
various cancer models, such as sarcoma, lymphocytic leukaemia
and leukaemia grown as a solid tumour (Tsuruo et al, 1983; Merry
et al, 1991; Pommerenke and Volm, 1995). Much attention has
focussed on glioma as a target for tricyclics and there have been
some preliminary clinical studies in humans using chlorimipra-
mine therapeutically (Beaney et al, 2005).
Based upon their apparent sensitivity to tricyclics in vitro,
we hypothesised that they would have a protective effect
against glioma and colorectal cancer. We therefore conducted a
case–control study using the GPRD to investigate this. In addition
to examining these two tumour types, we also studied certain other
cancers to look for specificity of any effect.
MATERIALS AND METHODS
A matched case–control study was used to investigate possible
relations between drug usage and cancer incidence. Cases were
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ydefined as any person with a recorded diagnosis of brain tumour,
breast, colorectal, lung or prostate cancer within the GPRD
(diagnosis codes available on request); gliomas were considered
separately. We excluded cases with o5 years of follow-up before
the first recorded diagnosis of the relevant cancer, aged o18 years
or with a diagnosis of any malignancy before the index cancer.
Controls were individuals contributing data at the time of the case
index date, with at least 5 years of follow-up before that date and
with no recorded diagnosis of cancer. They were matched to cases
by year of birth, gender and GP practice in a ratio of 2:1 where
possible.
The GPRD is a prospectively gathered, anonymised database
encompassing around 500 GP practices throughout the United
Kingdom, and is the largest of its type in the world, with around
45 million patient-years of data spread across B6.5 million
patients. It provides data on patients including clinical diagnoses,
treatments and outcomes. The database was established in 1987,
with its development corresponding to the increased computerisa-
tion of GP practices, and its validity has been well documented
(Jick et al, 1991, 2003; Fombonne et al, 2004; Herrett et al, 2010).
The primary exposure was the use of any tricyclic antidepres-
sant (section 4.3.3 of the British National Formulary (BNF)).
We abstracted data on all such prescriptions at least 1 year before
the date of diagnosis of the index cancer (or the equivalent pseudo-
diagnosis date of the cancer for controls). We first created a
binary variable defining a tricyclic user as anyone with a repeat
prescription for any tricyclic antidepressant, and comparing these
with non-users. To allow assessment of dose response we
determined the mean dose received across all exposed days for
each patient. This was standardised across drug types by dividing
by the maximum recommended doses for each drug (determined
from the BNF). Each patient was then placed in a ‘high dose’,
‘low dose’ or ‘unexposed’ category, such that those exposed were
divided equally into high- and low-dose categories. Length/
consistency of exposure was assessed by determining the number
of days of exposure over a 10-year period before the index date.
Any patient contributing data for less time was excluded for this
part of the analysis. Exposed patients were then divided into two
groups of equal size. In order to assess any potential confounding
by indication, SSRI use was investigated by categorising those
exposed to only SSRIs, only tricyclics, and both SSRIs and
tricyclics. We extracted data on smoking status, body mass index
(BMI), alcohol use, diagnosis of depression and prescriptions for
NSAIDs and statins, which we considered as possible confounders.
Statistical methods
Data were analysed with conditional logistic regression, initially
using univariate analysis, and then using a multivariate model.
Results were presented as odds ratios (ORs), with 95% confidence
intervals (CIs). Potential confounders were retained in the model
if their inclusion produced a 10% variation in the measured size
of effect. Analyses were performed on all cancer types together,
followed by individual cancer types to look for specific effects.
Trend was tested for by including dose/exposure duration in the
conditional logistic regression model as a single, ordered
categorical variable, with P-values obtained using the likelihood-
ratio test. All data handling and analysis was done using Stata
v10.1 SE (Statacorp, College Station, TX, USA).
RESULTS
We identified 31953 cases with which 61591 controls were
matched by age and gender. The cases consisted of 1372 cancers
of the nervous system (of which 773 were gliomas), 10293 of the
breast, 6232 colorectal, 6537 of the lung and 6537 of the prostate.
Median age of patients across all cancer types was 68.2. Females
made up 50.7% (16212) of the study and had a median age of 65.6,
and males had a median age of 70.9. In all, 18.9% of cases and
17.6% of controls were exposed to one or more prescriptions for a
tricyclic before one year before the index date. These data are
summarised in Table 1.
As can be seen from Table 2, smoking was associated with an
increased risk of cancer (OR¼1.47, CI¼1.42–1.53), almost
entirely attributable to lung cancer, with an OR of 7.4
(CI¼6.74–8.12) in smokers compared with non-smokers. There
is a slight increase in risk of cancer for alcohol users (OR¼1.09,
CI¼1.05–1.14), which was mostly because of breast (OR¼1.11,
CI¼1.04–1.18) and colorectal cancers (OR¼1.12, CI¼1.02–
1.23). There is an apparent decrease in cancer risk as BMI
increases, mainly found in lung cancer patients, where the decrease
is caused by confounding by smoking status, and is not statistically
significant if only non-smokers are considered. NSAID use is
not significantly different for all cancers together, but shows
a significant reduction in colorectal cancer (OR¼0.93, CI¼0.87–
0.99), as reported previously (Cuzick et al, 2009).
Analysis with tricyclic use coded as a binary variable (Table 3)
demonstrates a significant reduction in tricyclic usage in colorectal
cancer patients compared with controls (multivariate OR¼0.84,
Table 1 Characteristics
Cases Controls
Cancer Number % Number %
All
Total 31953 61591
Male 15740 49.3 29998 48.7
Female 16212 50.7 31593 51.3
Mean age 68.3
Glioma
Total 773 1502
Male 468 60.3 906 60.5
Female 305 39.7 596 39.5
Mean age 60.1
Colorectal
Total 6232 12010
Male 3496 56.1 6704 55.8
Female 2736 43.9 5306 44.2
Mean age 70.9
Brain (excl glioma)
Total 599 1164
Male 214 35.7 413 35.5
Female 385 64.3 751 64.5
Mean age 65.8
Breast
Total 10293 20096
M a l e —— ——
Female 10293 100.0 20096 100.0
Mean age 62.5
Lung
Total 6537 12514
Male 4035 61.73 7653 61.16
Female 2502 38.27 4861 38.84
Mean age 71.0
Prostate
Total 7531 14329
Male 7531 100.0 14329 100.0
Female — — — —
Mean age 72.5
A summary of the characteristics of the population, including for each of the cancers.
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patients compared with controls, with a larger effect estimate
(OR¼0.59, CI¼0.42–0.81). For most cancers, we found little
evidence of confounding by the available potential confounders,
except for lung cancer, where smoking status had a large
confounding effect. The significant increase in tricyclic use
observed in the univariate model (OR¼1.30, CI¼1.19–1.42) is
greatly reduced when adjusted for confounders (OR¼1.14,
CI¼1.02–1.28). Other cancers show little variation in tricyclic
usage, with ORs very close to one.
For glioma, selective serotonin reuptake inhibitor (SSRI) use
without tricyclic use showed little deviation between cases and
controls (OR¼0.96, CI¼0.61–1.53). This is in contrast to tricyclic
use with (OR¼0.50, CI¼0.27–0.92) and without (OR¼0.74,
CI¼0.52–1.06) SSRI use. Colorectal cancer was similar to glioma
in terms of exclusive SSRI use (OR¼0.95, CI¼0.81–1.12), and
showed a similar pattern to the above binary analysis for tricyclic
use with SSRI use (OR¼0.85, CI¼0.70–1.02) and exclusive
tricyclic use (OR¼0.85, CI¼0.76–0.95).
When divided into ‘low’ and ‘high’ dose exposure (Table 4),
tricyclic use is significantly lower at high doses for both glioma
(OR¼0.49, CI¼0.30–0.78) and colorectal cancer (OR¼0.79,
CI¼0.67–0.93). Highly significant trends validate these findings
further for glioma (P¼0.0005) and colorectal cancer (P¼0.0010).
Other cancer types were considered in the same way, although no
notable or statistically significant trends were present (data not
shown). We then investigated relationships with duration of
tricyclic exposure. As with the dose analysis, long-term use is
significantly lower in glioma (OR¼0.36, CI¼0.19–0.69) and
colorectal cancer (OR¼0.82, CI¼0.68–0.97). Highly significant
trends were observed again for glioma (P¼0.0005) and colorectal
cancer (P¼0.0086). No notable or statistically significant trends
were present for other cancers (data not shown).
DISCUSSION
This study finds that tricyclic use may be associated with a
subsequent reduction in the risk of glioma and colorectal cancer.
These protective effects appear to be specific to these particular
cancers, as it was not observed for the other cancers studied,
although we cannot rule out a protective effect in cancers not
covered. The data also indicate that these apparent protective
effects are greatest for patients receiving high-dose prescriptions
over a long period.
Our data have certain important strengths. Our use of routinely
collected general practice records (from the GPRD) ensured that
there was no opportunity for recall bias to effect the ascertainment
of exposures. In addition, by selecting all relevant malignancies
within the population and a random sample of the suitable
controls, we eliminated the possibility of selection bias. However,
our data selection does have some weaknesses. Although the
numerous validation studies of various diagnoses suggest that our
outcomes were accurately coded, as the electronic recording
of prescription data does for our primary exposure, we cannot be
equally confident about the recording of all potential confounders.
As Table 2 shows, there are much missing data with respect to
Table 2 Covariates
Exposure Status Case Control OR 95% CI
Smoking status No 15369 32153 1
Ex 5911 10263 1.23 1.19 1.28
Yes 7978 11615 1.47 1.42 1.53
Missing 2695 7560 0.69 0.65 0.72
Alcohol use No 4778 9542 1
Ex 348 572 1.24 1.08 1.43
Yes 21028 38670 1.09 1.05 1.14
Missing 5799 12807 0.87 0.83 0.91
Mean BMI Normal 10713 19466 1
Underweight 701 1020 1.26 1.14 1.39
Overweight 10086 19005 0.96 0.93 1.00
Obese 3191 6240 0.93 0.89 0.98
Morbidly obese 961 2008 0.88 0.81 0.95
Missing 6301 13852 0.79 0.76 0.82
NSAID use No 21122 41006 1
Yes 10831 20585 1.02 0.99 1.05
Statin use No 26957 51933 1
Yes 4996 9658 1.00 0.96 1.04
Depression No 23890 47458 1
Yes 8063 14133 1.15 1.11 1.19
Abbreviations: Ex¼former smoker; NSAID¼non-steroidal anti-inflammatory drug;
BMI¼body mass index; OR¼odds ratio; CI¼confidence interval. Changes in cancer
risk for each of the covariates. These results are for all the studied cancer types
grouped together, and hence do not describe differences in exposures between
cancer type (see text).
Table 3 Binary analysis
Univariate Multivariate*
Cancer type Exposed Case Control OR 95% CI OR 95% CI
Glioma No 706 1317 1 1
Yes 67 185 0.66 0.49 0.89 0.59 0.42 0.81
Colorectal No 5574 10543 1 1
Yes 658 1467 0.85 0.77 0.94 0.84 0.75 0.94
Brain No 505 1013 1 1
(excl glioma) Yes 94 151 1.26 0.95 1.67 1.00 0.72 1.38
Breast No 8651 16834 1 1
Yes 1642 3262 0.98 0.92 1.05 0.97 0.91 1.04
Lung No 5555 10992 1 1
Yes 982 1522 1.30 1.19 1.42 1.14 1.02 1.28
Prostate No 6861 13112 1 1
Yes 670 1217 1.06 0.96 1.17 0.94 0.84 1.04
All No 27841 53790 1 1
Yes 4112 7801 1.03 0.99 1.07 0.93 0.89 0.97
Abbreviations: OR¼odds ratio; CI¼confidence interval. Patients with repeat
prescriptions for tricyclics were defined as exposed. *Corrected for smoking status,
diagnosis of depression, alcohol use and BMI. NSAID use corrected for in colorectal
cancer only.
Table 4 Dose and duration
Cancer
Exposure
status Case Control OR 95% CI P-trend
Dose
Glioma Unexposed 707 1323 1
Low dose 38 97 0.67 0.45 1.01
High dose 28 82 0.49 0.30 0.78 0.0005
Colorectal Unexposed 5592 10595 1
Low 382 821 0.87 0.76 1.00
High 258 594 0.79 0.67 0.93 0.0010
Duration (days)
Glioma Unexposed 399 1051 1
1–117 22 71 0.65 0.37 1.13
4117 14 75 0.36 0.19 0.69 0.0005
Colorectal Unexposed 3598 7752 1
1–117 345 747 0.84 0.70 1.01
4117 305 785 0.82 0.68 0.97 0.0086
Abbreviations: OR¼odds ratio; CI¼confidence interval. Glioma and colorectal
cancer dose-response and duration results. Other cancer types did not show
consistent dose-response relationships. All analyses in this table are corrected for
smoking status, diagnosis of depression, alcohol use and BMI. NSAID use corrected
for in colorectal cancer only.
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confounding by these factors. However, we believe that except for
lung cancer where this is clearly an issue (and residual
confounding by smoking might account for the positive associa-
tion with tricyclics), the near total lack of confounding detected
argues that any such residual will be minor. A potentially greater
issue is that we lack any data on other potential confounders such
as diet and exercise, and hence their impact on the results cannot
be assessed.
Another strength of our study is that by studying several
cancers, we have demonstrated that the protective effect of
tricyclics appears to be specific to certain malignancies. Because
of the study size, we have also been able to demonstrate
that longer-term use and higher doses of tricyclics appear to give
greater protection from glioma and colorectal cancers. As the
proposed anticancer mechanism of action is a mitochondrial one
(Daley et al, 2005) and independent of the psychoactive mechan-
ism of action, there is reason to believe that these findings are
generalisable, and not restricted only to a ‘depressed’ population.
Confounding by indication is important and if SSRIs are
considered as were tricyclics, their pattern is similar (data not
shown), possibly because their use is predictive of tricyclic use. If
patients using SSRIs exclusively (i.e., no tricyclics) are considered,
most of the effect disappears. The multivariate results were
adjusted for diagnosis of depression, and this adjustment
increased the apparent protective effect of tricyclics. It would
seem more biologically plausible for depression to increase cancer
risk than decrease it, and it is therefore likely that depression is a
proxy for high-dose tricyclics (as it is usually treated with a higher
dose than other indications, such as pain). This is supported by the
relation with dose (where those without depression have a higher
proportion of low dose and vice versa).
Previous studies have examined tricyclics and the incidence of
colorectal (Xu et al, 2006), prostate (Tamim et al, 2007), breast
(Cotterchio et al, 2000; Gonzalez-Perez and Garcia Rodriguez,
2005; Fulton-Kehoe et al, 2006; Wernli et al, 2009) and lung
cancers (Toh et al, 2007), but have shown little consistency, and
significant evidence has been found to link tricyclics with cancer.
A study on colorectal cancer (Xu et al, 2006) hypothesised that
tricyclics are genotoxic, and therefore increase cancer risk,
but, their results suggest a nonsignificant protective effect, as did
another recent study (Patricia et al, 2009). Our findings
for colorectal cancer fit well with these data, the statistically
significant protection being a function of our greater numbers.
The previous lung cancer study (Toh et al, 2007) showed an
apparent increase in risk with tricyclic use, which is largely
mitigated by adjusting for confounders (including smoking
status), as with our data.
We have found a significant reduction in incidence of colorectal
cancer and glioma, consistent with previous laboratory evidence
(Daley et al, 2005), and not inconsistent with other epidemiological
studies. The findings show specificity of protection for those
malignancies originally hypothesised and show a dose-response
and a clear temporal relationship. It is credible that our
associations may be causal, although the modest size of the effect
limits the potential of these drugs as a chemopreventative agent in
the general population. As glioma is a rare cancer with ill-defined
high-risk groups, prescribing chemopreventative drugs are of
limited value in the general population; thus, we estimate that
B60000 people would need to be treated (for 4117 days) in order
to prevent one glioma. Groups at increased risk of colorectal
cancer (e.g., those with a familial or other genetic predisposition)
might still represent an appropriate group for an RCT as they
would have the best chance of benefiting from chemoprevention,
here although one would need to balance potential benefits against
possible side effects.
If the antineoplastic effects of tricyclics are to be therapeutically
useful, it is likely to follow identification of a potent compound
within the group, or in postdiagnosis treatment of colorectal
cancer and glioma. Thus, aspirin, a recognised prophylactic for
colorectal cancer, has recently been found to reduce colorectal
cancer mortality when used after diagnosis (Chan et al, 2009; Zell
et al, 2009), and to an extent achieved previously only by far more
toxic compounds. It would therefore be useful to determine
whether tricyclics have similar effects on colorectal cancer and
glioma.
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